ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 – FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS

Glioblastoma (GBM) remains the deadliest of all primary brain tumors with very few effective treatment options. Recently, we reported that high AXL expression is correlated with poor prognosis in GBM patients and demonstrated the therapeutic benefits of targeting AXL, a member of TAM receptor tyrosi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Ghosh, Sadashib, Sadahiro, Hirokazu, Kang, Kyung-Don, Gibson, Justin T, Minata, Mutsuko, Yu, Hai, Shi, Junfeng, Chhipa, Rishi, Chen, Zhihong, Lu, Songjian, Simoni, Yannick, Furuta, Takuya, Sabit, Hemragul, Zhang, Suojun, Bastola, Soniya, Yamaguchi, Shinobu, Alsheikh, Heba Allah, Komarova, Svetlana, Wang, Jun, Kim, Sung-Hak, Hambardzumyan, Dolores, Lu, Xinghua, Newell, Evan W, Dasgupta, Biplab, Nakada, Mitsutoshi, Lee, L James, Nabors, L Burt, A. Norian, Lyse, Nakano, Ichiro
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216174/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.054
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares